



WEDNESDAY 9th December 2015 COMMENCING 9.30 AM

AT THE ANGEL HOTEL, ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting** 1/AWMSG/1215
5. **Chairman's report (verbal update)**
6. **All Wales Syringe Driver Chart** 2/AWMSG/1215
7. **Appraisal 1: Full Submission** 3/AWMSG/1215
Empagliflozin (Jardiance[®]) for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance Appendices
8. **Appraisal 2: Limited Submission** 4/AWMSG/1215
Efavirenz (Sustiva[®]) indicated in antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children 3 months of age and weighing at least 3.5 kg to children 3 years of age Appendices
9. **Appraisal 3: Limited Submission** 5/AWMSG/1215
Atazanavir/cobicistat (Evotaz[®]) in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir Appendices

To protect commercial confidentiality, the next three appraisals will be conducted in private and the meeting will close to the public

10. **Appraisal 4: Full Submission WPAS** 6/AWMSG/1215
Macitentan (Opsumit[®]) as monotherapy or in combination, for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III

- | | |
|---|----------------------------|
| 11. Appraisal 5: Full Submission WPAS
Cetuximab (Erbix[®]) for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer, in combination with irinotecan-based chemotherapy, in first-line in combination with FOLFOX, as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan | 7/AWMSG/1215
Appendices |
| 12. Appraisal 6: Full Submission WPAS
Ivacaftor (Kalydeco[®]) for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following gating (class III) mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R | 8/AWMSG/1215
Appendices |

Date of next meeting: 24th February 2016 in Abergavenny